December 21, 2024 - 04:21

CFRA Research Chief Investment Strategist Sam Stovall recently shared his insights on the market outlook for 2025, expressing a tempered sense of optimism. Following the release of softer-than-expected Personal Consumption Expenditures (PCE) data, Stovall noted that markets are "breathing a sigh of relief." He highlighted several encouraging trends, including a weakening US dollar and rising gold prices, which he believes contribute to a generally positive market environment.
Despite this optimism, Stovall warned of potential volatility in the coming weeks as investors may seek to lock in profits before the new year. Looking further ahead, he projects that the S&P 500 could reach 6,585 by the end of 2025. Stovall characterized his outlook as being "a bull with a lowercase 'b'," reflecting a cautious approach. He emphasized the historical challenges faced by third-year bull markets, citing that only 3 out of 11 have successfully transitioned beyond their second year. As Stovall anticipates market growth, he acknowledges the likely bumps along the road ahead.
May 9, 2026 - 22:04
Compass Diversified Q1 Earnings Call HighlightsCompass Diversified, the publicly traded holding company known as CODI, reported its first-quarter 2026 earnings this week, with management framing the period as one of disciplined execution. Chief...
May 9, 2026 - 00:34
Urbana Corporation Has Filed 2026 First Quarter Interim Financial StatementsTORONTO - Urbana Corporation has submitted its unaudited interim financial statements and management discussion for the first quarter of 2026. The filing covers the three-month period ending March...
May 8, 2026 - 11:59
Australia regulator calls for urgent cybersecurity action to counter MythosAustralia`s corporate watchdog has called on the country`s financial industry to take urgent steps to address cybersecurity risks posed by advanced artificial intelligence systems, including a...
May 7, 2026 - 20:22
IN8bio Reports First Quarter 2026 Financial Results and Recent Business HighlightsIN8bio, a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies, announced its financial results for the first quarter of 2026 along with key business updates. The...